gebhart/patrepeval huggingface dataset:
Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications (2010)

Affibody molecules are a class of engineered affinity proteins with proven potential for therapeutic, diagnostic and biotechnological applications. Affibody molecules are small (6.5 kDa) single domain proteins that can be isolated for high affinity and specificity to any given protein target. Fifteen years after its discovery, the Affibody technology is gaining use in many groups as a tool for creating molecular specificity wherever a small, engineering compatible tool is warranted. Here we summarize recent results using this technology, propose an Affibody nomenclature and give an overview of different HER2-specific Affibody molecules. Cumulative evidence suggests that the three helical scaffold domain used as basis for these molecules is highly suited to create a molecular affinity handle for vastly different applications.
A peptide from the GAP-binding domain of the ras-p21 protein and azatyrosine block ras-induced maturation of Xenopus oocytes. (1992)

The ras-oncogene-encoded p21 protein causes malignant transformation of NIH 3T3 cells and maturation of Xenopus oocytes when microinjected into these cells. P21 is known to interact with GTPase activating protein (GAP) intracellularly. Residues 32-45 of p21 have been implicated in interacting with GAP. In a previous study, we demonstrated that a synthetic peptide containing residues 35-47 from the GAP-binding region of p21 could block in vivo the effects of oncogenic p21 protein. It has also been found that an antibiotic, azatyrosine, blocks ras-initiated cell transformation. We now demonstrate that both of these agents inhibit the ras-p21 protein-induced maturation of Xenopus oocytes in a dose-related manner when microinjected into oocytes. The effects of each of these agents is specific. Both agents block insulin-induced maturation of oocytes, a process which is known to involve activation of endogenous normal p21 protein. On the other hand, neither agent inhibited oocyte maturation induced by progesterone, which is known to initiate oocyte maturation by ras-independent pathways. The inhibitory effects of the peptide were not mimicked by a control peptide from the CD4 receptor protein. Furthermore, the effect of azatyrosine was not mimicked by L-tyrosine. These results suggest that both the peptide and azatyrosine have potent anti-ras effects intracellularly.
Therapeutic Applications of Extracellular Vesicles: Clinical Promise and Open Questions (2014)

This review provides an updated perspective on rapidly proliferating efforts to harness extracellular vesicles (EVs) for therapeutic applications. We summarize current knowledge, emerging strategies, and open questions pertaining to clinical potential and translation. Potentially useful EVs comprise diverse products of various cell types and species. EV components may also be combined with liposomes and nanoparticles to facilitate manufacturing as well as product safety and evaluation. Potential therapeutic cargoes include RNA, proteins, and drugs. Strategic issues considered herein include choice of therapeutic agent, means of loading cargoes into EVs, promotion of EV stability, tissue targeting, and functional delivery of cargo to recipient cells. Some applications may harness natural EV properties, such as immune modulation, regeneration promotion, and pathogen suppression. These properties can be enhanced or customized to enable a wide range of therapeutic applications, including vaccination, improvement of pregnancy outcome, and treatment of autoimmune disease, cancer, and tissue injury.
DNA cleavage by a metal chelating tricationic porphyrin (1989)

ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTDNA cleavage by a metal chelating tricationic porphyrinJohn T. Groves and Thomas P. FarrellCite this: J. Am. Chem. Soc. 1989, 111, 13, 4998–5000Publication Date (Print):June 1, 1989Publication History Published online1 May 2002Published inissue 1 June 1989https://doi.org/10.1021/ja00195a074RIGHTS & PERMISSIONSArticle Views203Altmetric-Citations24LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InReddit PDF (386 KB) Get e-Alerts Get e-Alerts
Dystrophin expression improves myofiber survival in mdx muscle following intramuscular plasmid DNA injection (1993)

Expression of Becker-like and full-length human dystrophins was stable for at least 6 months in mdx mouse muscle following intramuscular plasmid DNA injection. Intramuscular injection of a single plasmid DNA encoding both luciferase and dystrophin resulted in stable luciferase expression for at least 2 months in mdx muscle, whereas injection of plasmid DNA encoding only luciferase did not result in stable luciferase expression. These results suggest that expression of either full-length or Becker-like dystrophins protects mdx mouse myofibers from degeneration.
Future of rAAV Gene Therapy: Platform for RNAi, Gene Editing, and Beyond (2017)

The use of recombinant adeno-associated viruses (rAAVs) ushered in a new millennium of gene transfer for therapeutic treatment of a number of conditions, including congenital blindness, hemophilia, and spinal muscular atrophy. rAAV vectors have remarkable staying power from a therapeutic standpoint, withstanding several ebbs and flows. As new technologies such as clustered regularly interspaced short palindromic repeat genome editing emerge, it is now the delivery tool-the AAV vector-that is the stalwart. The long-standing safety of this vector in a multitude of clinical settings makes rAAV a selling point in the advancement of approaches for gene replacement, gene knockdown, gene editing, and genome modification/engineering. The research community is building on these advances to develop more tailored delivery approaches and to tweak the genome in new and unique ways. Intertwining these approaches with newly engineered rAAV vectors is greatly expanding the available tools to manipulate gene expression with a therapeutic intent.
Intranasal Vaccination with AAV5 and 9 Vectors Against Human Papillomavirus Type 16 in Rhesus Macaques (2012)

Cervical cancer is the second most common cancer in women worldwide. Persistent high-risk human papillomavirus (HPV) infection has been identified as the causative event for the development of this type of cancer. Recombinant adeno-associated viruses (rAAVs) are currently being developed and evaluated as vaccine vector. In previous work, we demonstrated that rAAVs administered intranasally in mice induced high titers and long-lasting neutralizing antibodies against HPV type 16 (HPV16). To extend this approach to a more human-related species, we immunized rhesus macaques (Macaca mulatta) with AAVs expressing an HPV16 L1 protein using rAAV5 and 9 vectors in an intranasal prophylactic setting. An rAAV5-L1 vector followed by a boost with rAAV9-L1 induced higher titers of L1-specific serum antibodies than a single rAAV5-L1 immunization. L1-specific antibodies elicited by AAV9 vector neutralized HPV16 pseudovirions and persisted for at least 7 months post immunization. Interestingly, nasal application of rAAV9 was immunogenic even in the presence of high AAV9 antibody titers, allowing reimmunization with the same serotype without prevention of the transgene expression. Two of six animals did not respond to AAV-mediated intranasal vaccination, although they were not tolerant, as both developed antibodies after intramuscular vaccination with HPV16 virus-like particles. These data clearly show the efficacy of an intranasal immunization using rAAV9-L1 vectors without the need of an adjuvant. We conclude from our results that rAAV9 vector is a promising candidate for a noninvasive nasal vaccination strategy.
Ultrathin high-resolution flexographic printing using nanoporous stamps (2016)

Since its invention in ancient times, relief printing, commonly called flexography, has been used to mass-produce artifacts ranging from decorative graphics to printed media. Now, higher-resolution flexography is essential to manufacturing low-cost, large-area printed electronics. However, because of contact-mediated liquid instabilities and spreading, the resolution of flexographic printing using elastomeric stamps is limited to tens of micrometers. We introduce engineered nanoporous microstructures, comprising polymer-coated aligned carbon nanotubes (CNTs), as a next-generation stamp material. We design and engineer the highly porous microstructures to be wetted by colloidal inks and to transfer a thin layer to a target substrate upon brief contact. We demonstrate printing of diverse micrometer-scale patterns of a variety of functional nanoparticle inks, including Ag, ZnO, WO<sub>3</sub>, and CdSe/ZnS, onto both rigid and compliant substrates. The printed patterns have highly uniform nanoscale thickness (5 to 50 nm) and match the stamp features with high fidelity (edge roughness, ~0.2 μm). We derive conditions for uniform printing based on nanoscale contact mechanics, characterize printed Ag lines and transparent conductors, and achieve continuous printing at a speed of 0.2 m/s. The latter represents a combination of resolution and throughput that far surpasses industrial printing technologies.
Suppression of human glioma growth by adenovirus-mediated Rb gene transfer (1998)

These findings provide direct evidence that inactivation of the retinoblastoma protein is a critical event in gliomas, and suggest that the restoration of wild-type retinoblastoma activity in these tumors may have therapeutic utility.
Mouse embryonic transforming growth factors related to those isolated from tumor cells. (1982)

Growth factors with the two characteristic properties of sarcoma growth factor, the ability to stimulate anchorage-independent growth of normal mouse or rat fibroblasts and the ability to compete with 125I-labeled epidermal growth factor for receptor binding, can be isolated from 12- to 13-day-old normal mouse embryos of various strains. Two size classes of the transforming factor from embryo cells can be isolated with apparent molecular weights of 20,000 and 10,000. The lower-molecular-weight factor has been purified several hundred-fold and has the same properties as the peptides with a molecular weight of 10,000 produced by mouse sarcoma virus-transformed 3T3 cells. Whole-mouse embryos contain approximately 10% as much sarcoma growth factor per g of tissue as do the murine sarcoma virus-transformed cells; how it is distributed among the embryonic tissues remains to be determined.
Biological Role of Estrogen Receptor β in Salivary Gland Adenocarcinoma Cells (2006)

These results clearly showed that ERbeta nongenomic signaling is active in salivary gland cells and has a biological role in migration, presumably via the stimulation of ERK1/2. In future, the findings of this study might have clinical importance as several ERbeta-selective agonists are currently being available, and these could potentially be used for therapeutic targeting of ERbeta-positive salivary tumors.
Formation Evaluation From Logging on Cuttings (1998)

Summary This paper presents an overview of a vast research project called Formation Evaluation 2000, which was undertaken by Agip SpA and was aimed at characterizing in real time the formations encountered during drilling by means of measurements on drill chips. To date, the project has demonstrated the feasibility of obtaining representative values of P- and S-wave velocities, rock strength and deformability, permeability, porosity, density, residual fluid con- tent, and saturation. Further work is under way to determine the pore-size distribution, the thermal expansion coefficient, and the electrical resistivity of the rocks from measurements on cuttings. The paper presents the methodology used to systematically develop these technologies and illustrates the results obtained to date during the various sequences of the research, i.e., the primary design of the measurements, laboratory tuning, and field applicability. Furthermore, the paper presents a series of field cases in which these techniques were used, to highlight the industrial applications of such a package of measurements.
NADPH Oxidase 4 Is Expressed in Pulmonary Artery Adventitia and Contributes to Hypertensive Vascular Remodeling (2014)

These findings indicate that Nox4 is prominently expressed in the adventitia and contributes to altered fibroblast behavior, hypertensive vascular remodeling, and development of PH.
Electrochemotherapy, electrogenetherapy, and transdermal drug delivery : electrically mediated delivery of molecules to cells (2000)

In Electrochemotherapy, Electrogenetherapy, and Transdermal Drug Delivery, leading experts comprehensively review all aspects of the delivery of therapeutic molecules to cells using electrical impulses-i.e., the extraordinarily promising new areas of electrogene therapy, electrochemotherapy, and transdermal drug delivery. Their survey ranges from outlines of the basic physical principles that govern cell permeabilization by pulsed electric fields, to descriptions of the current state-of-the-art in instrumentation and electrodes, to summaries of preclinical and clinical trial results. The authors focus on drug, gene, and transdermal delivery techniques, providing detailed examples of drug delivery using electric fields from a variety of pulse generators and electrodes. The protocols cover almost every variation in procedure and/or apparatus so that investigators can readily identify the method needed for their own work, or adapt one to their particular purposes. Comprehensive and authoritative, Electrochemotherapy, Electrogenetherapy, and Transdermal Drug Delivery provides entré to an immensely practical set of in vivo electroporation techniques, including electrogene therapy, electrochemotherapy, and transdermal drug delivery-techniques holding great promise for all those working toward better therapies for in cancer, metabolic diseases, and vaccination
Optical Fiber Surface Plasmon Resonance Sensor for an Aqueous Environment (1997)

Within last years optical waveguide sensors based on resonant excitation of surface plasmon waves have received a great deal of interest and various sensing configurations employing optical fibers [1,2] and integrated optical waveguide [3, 4] have been realized.
Multiple hormone-inducible enhancers as mediators of differential transcription. (1986)

Sets of genes under a common regulatory control in a given cell type are often differentially transcribed. The possibility that this differential transcription can be modulated by the number or strength of cis-acting regulatory sequences associated with a given gene was tested by using the glucocorticoid-responsive enhancer element associated with the mouse mammary tumor virus promoter. Results indicate that differential levels of hormone-inducible gene expression can be modulated in an additive way by the number of glucocorticoid-responsive enhancers associated with this promoter. Realization of these effects shows little preference for position of the additional elements with respect to the promoter. When sequences that bind the glucocorticoid receptor in vitro with somewhat lower affinity than the enhancer were tested, these additive effects were not detected. The results support that differential transcription of genes subject to a common regulatory control can be mediated, at least in part, by the number or strength of their associated cis-acting regulatory sequences.
Adenosine in Sepsis and Septic Shock (2003)

Sepsis and septic shock account for substantial morbidity and mortality in intensive care units. Nuclear factor-kB (NF-kB) activation, and elevated concentrations of macrophage migration inhibitory factor, tumor necrosis factor-a (TNF-a), interleukin-1 (IL-1), IL-6, reactive oxygen species, and inducible nitric oxide play a major role in the pathobiology of sepsis and septic shock. In experimental animals, adenosine and its analogs prevented the activation of NF-kB, downregulated inflammation, suppressed leukotriene biosynthesis and the production of IL-12 and TNF-a, and decreased oxidative stress. In addition, myocardial responsiveness to insulin was restored by adenosine administration during acute endotoxic shock, and wound healing was enhanced. This suggests that adenosine, its structural analogs, or adenosine kinase inhibitors may form a novel therapeutic approach in the treatment of sepsis and other
Plastic Solar Cells (2001)

Recent developments in conjugated-polymer-based photovoltaic elements are reviewed. The photophysics of such photoactive devices is based on the photo-induced charge transfer from donor-type semiconducting conjugated polymers to acceptor-type conjugated polymers or acceptor molecules such as Buckminsterfullerene, C60. This photo-induced charge transfer is reversible, ultrafast (within 100 fs) with a quantum efficiency approaching unity, and the charge-separated state is metastable (up to milliseconds at 80 K). Being similar to the first steps in natural photosynthesis, this photo-induced electron transfer leads to a number of potentially interesting applications, which include sensitization of the photoconductivity and photovoltaic phenomena. Examples of photovoltaic architectures are presented and their potential in terrestrial solar energy conversion discussed. Recent progress in the realization of improved photovoltaic elements with 3 % power conversion efficiency is reported.
Effect of ionic strength and cationic DNA affinity binders on the DNA sequence selective alkylation of guanine N7-positions by nitrogen mustards (1990)

Large variations in alkylation intensities exist among guanines in a DNA sequence following treatment with chemotherapeutic alkylating agents such as nitrogen mustards, and the substituent attached to the reactive group can impose a distinct sequence preference for reaction. In order to understand further the structural and electrostatic factors which determine the sequence selectivity of alkylation reactions, the effect of increased ionic strength, the intercalator ethidium bromide, AT-specific minor groove binders distamycin A and netropsin, and the polyamine spermine on guanine N7-alkylation by L-phenylalanine mustard (L-Pam), uracil mustard (UM), and quinacrine mustard (QM) was investigated with a modification of the guanine-specific chemical cleavage technique for DNA sequencing. For L-Pam and UM, increased ionic strength and the cationic DNA affinity binders dose dependently inhibited the alkylation. QM alkylation was less inhibited by salt (100 mM NaCl), ethidium (10 microM), and spermine (10 microM). Distamycin A and netropsin (100 microM) gave an enhancement of overall QM alkylation. More interestingly, the pattern of guanine N7-alkylation was qualitatively altered by ethidium bromide, distamycin A, and netropsin. The result differed with both the nitrogen mustard (L-Pam less than UM less than QM) and the cationic agent used. The effect, which resulted in both enhancement and suppression of alkylation sites, was most striking in the case of netropsin and distamycin A, which differed from each other. DNA footprinting indicated that selective binding to AT sequences in the minor groove of DNA can have long-range effects on the alkylation pattern of DNA in the major groove.
Ultrasensitive Clinical Enumeration of Rare Cells ex Vivo Using a Micro-Hall Detector (2012)

The ability to detect rare cells (<100 cells/ml whole blood) and obtain quantitative measurements of specific biomarkers on single cells is increasingly important in basic biomedical research. Implementing such methodology for widespread use in the clinic, however, has been hampered by low cell density, small sample sizes, and requisite sample purification. To overcome these challenges, we have developed a microfluidic chip-based micro-Hall detector (μHD), which can directly measure single, immunomagnetically tagged cells in whole blood. The μHD can detect single cells even in the presence of vast numbers of blood cells and unbound reactants, and does not require any washing or purification steps. In addition, the high bandwidth and sensitivity of the semiconductor technology used in the μHD enables high-throughput screening (currently ~10(7) cells/min). The clinical use of the μHD chip was demonstrated by detecting circulating tumor cells in whole blood of 20 ovarian cancer patients at higher sensitivity than currently possible with clinical standards. Furthermore, the use of a panel of magnetic nanoparticles, distinguished with unique magnetization properties and bio-orthogonal chemistry, allowed simultaneous detection of the biomarkers epithelial cell adhesion molecule (EpCAM), human epidermal growth factor receptor 2 (HER2)/neu, and epidermal growth factor receptor (EGFR) on individual cells. This cost-effective, single-cell analytical technique is well suited to perform molecular and cellular diagnosis of rare cells in the clinic.
Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis (1987)

We assessed oral 5-aminosalicylic acid (5-ASA) prepared with a pH-sensitive polymer coating in 87 patients with mildly to moderately active ulcerative colitis in a double-blind, placebo-controlled trial. Patients were randomly assigned to receive 5-ASA at a dosage of either 4.8 or 1.6 g per day or placebo for six weeks. The outcome was monitored by flexible proctosigmoidoscopic examinations and physicians' assessments at three-week intervals and by patients' recordings of daily symptoms. Results showed 24 percent complete and 50 percent partial responses in those receiving 4.8 g of 5-ASA per day as compared with 5 percent complete and 13 percent partial responses in those receiving placebo (P less than 0.0001, rank-sum test). At a dosage of 1.6 g per day, the response was twice as good as with placebo, but the difference did not reach statistical significance (P = 0.51). Age, sex, duration of disease, duration of active symptoms, or extent of disease did not affect the clinical outcome. We conclude that oral 5-ASA administered in a dosage of 4.8 g per day is effective therapy, at least in the short term, for mildly to moderately active ulcerative colitis.